| Similar Articles |
|---|
 |
ONLINE
Jan/Feb 2002
Elaine N. Cheeseman |
IDdb3: Pharmaceutical Intelligence for the Third Millennium Are you looking for many types of drug pipeline information in one place? Interested in locating current pharmaceutical patent, company, or conference information? Do you need quick and easy access to this information?   |
Information Today
February 19, 2007
Tara Breton |
Elsevier Introduces Emscopes Database for Drug Information Emscopes is a more powerful product literature database (PLD) that is a directed at the specific needs of subscribing clients in pharmaceutical and biotech companies. |
Information Today
January 4, 2010 |
Thomson Reuters Links Drug Discovery and Literature Citation Databases Thomson Reuters announced it has connected its drug discovery database, Prous Science Integrity, to Web of Knowledge, its research platform. |
Information Today
September 1, 2015 |
InfoDesk Plans New Version of PipelinePlus Pipeline Plus simplifies drug pipeline searching and provides federated results and related drug news on a single platform. |
Information Today
November 14, 2011
Tara Breton |
New Pharmaceutical Information Tool Coming From Thomson Reuters--Cortellis The content of the system at the moment is limited to competitive intelligence, pipeline information gleaned from sources such as Thomson Reuters Pharma, and patent information from Dolphin. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. |
The Motley Fool
August 2, 2004
Charly Travers |
What's a Drug Worth? The value of small biotech companies is in their investigational drug programs. |
Information Today
November 29, 2004
Paula J. Hane |
Thomson Announces New Pharma Research Tool The Thomson Corp. is using the Online Information exhibition in London for the official launch of its new integrated research tool for the pharmaceutical and biotech industries. |
The Motley Fool
January 12, 2005
Charly Travers |
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. |
The Motley Fool
October 1, 2008
Brian Orelli |
3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear. |
Investment Advisor
December 2005
Greg B. Scott |
Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns. |
ONLINE
Mar/Apr 2009
Nelson et al. |
FEATURE: Implementing Federated Search at the University of Wyoming The allure of federated searching is potent in academic libraries. Students and faculty want to streamline their searching across web-based search engines, library collections, and the bibliographic databases to which the library subscribes. |
Pharmaceutical Executive
May 1, 2006
Madison, Chan & Seeger |
Making the Link The FDA recognizes that a new drug standard must evolve -- one of routine, proactive safety surveillance. But post-marketing safety studies are too slow. Here's how pharmaceuticals are using claims databases to solve the problem. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
August 23, 2004
Ben McClure |
Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest. |
Pharmaceutical Executive
May 1, 2007 |
Thoughtleader: Thomas Nagle, Strategic Pricing Group This industry consultant believes the U.S. government will soon follow Europe's lead in taking a greater hand in price negotiations, and pharma will need to be able to communicate the value that products offer. Here he discusses how pharma can meet that challenge. |
AskMen.com
Joshua Levine |
Selling Your Body To Science Have you ever thought about the number of voluntary patients who basically sell their bodies to clinical trials in the name of science? Well, the number is staggering and it can reach well into the thousands. The main reason being the large paycheck that comes with the job. |
Entrepreneur
May 2008
Mike Hogan |
Make it Easy The new crop of online databases is the most worker-friendly yet. |
Pharmaceutical Executive
July 30, 2007
Louis A. Morris |
Safety Net The new Culture of Drug Safety means embracing the benefit of no doubt about a product's pluses and its minuses. Pharma must learn how patients and prescribers weigh risks and how to spread the word about the advantages. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
Bio-IT World
July 11, 2002
Kevin Davies |
Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go. |
Searcher
January 2004
Carol Ebbinghouse |
If at First You Don't Succeed, Stop! Proposed legislation to set up new intellectual property right in facts themselves |
The Motley Fool
June 19, 2009
Brian Orelli |
Comparative Medicine Could Sink Your Stocks The government's plan will have a very unpredictable effect on companies. |
Chemistry World
December 2009 |
Column: In the pipeline Is the pharmaceutical industry churning out copycat versions of existing therapies? The author dispels a few myths about 'me-too' drugs |
